PCV71 COST-EFFECTIVENESS OF EZETIMIBE/SIMVASTATIN VERSUS SIMVASTATIN- WILL THE INCREASED RISK OF CANCER MAKE EZETIMIBE/SIMVASTATIN AN INAPPROPRIATE TREATMENT CHOICE?
Abstract
Authors
CC Wang AK Biddle JF Farley
CC Wang AK Biddle JF Farley
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now